AzTrials
AzTrials

Malaria (Plasmodium Falciparum)NCT07903324

Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings

A study testing Factory-treated lesu, Soaked lesu and Untreated lesu in people with Malaria (Plasmodium Falciparum) and Malaria Incidence, run by University of North Carolina, Chapel Hill at 1 site in Uganda.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The objective is to test the protective effect of permethrin-treated lesus against malaria in young children in refugee settings Read more about this study

Who is it for?
Ages 3 months to 99 yearsHealthy volunteers can take part
What is being tested?
Factory-treated lesu, Soaked lesu and Untreated lesu
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,350 participants
Where
1 siteUganda
Study dates
1 Sep 2027to 1 Sep 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 months to 99 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Mother is at least 18 years old
  • Dyad is considered a recent arrival ( < 18 months) to the catchment area of the settlement
  • Mother is the parent or legal guardian of a singleton (i.e., not a twin) infant 3-18 months of age
  • Has the ability to travel to a designated study site for visits and evaluation

Who cannot join

  • Participation in another study of malaria prevention
  • Known allergic reaction to permethrin
  • Has a known HIV diagnosis (or exposure) or sickle cell disease

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Ross Boyce, MD, MSc contact

919-966-2537

ross_boyce@med.unc.edu

Uganda1 site
  • Mbarara University of Science and Technology

    Mbarara

    Edgar Mulogo, PhD, MPH, 256-48540-20332

    Edgar Mulogo, PhD, MPH

Other trials in Uganda

About this study

Official title: Permethrin-Treated Baby Wraps for The Prevention of Malaria in Refugee Settings

The objective is to test the protective effect of permethrin-treated lesus against malaria in young children in refugee settings

Read the detailed description

The proposed study is a randomized, double-blind trial of factory-treated, long-lasting permethrin vs. soaked permethrin vs. sham-treated (control) wraps for the prevention of malaria in young children among newly arrived refugees. Participating mother-infant pairs will receive a new bed net and two permethrin-treated or untreated lesus at enrollment. The total sample size will be 675 mother-infant pairs with 225 pairs in each group. The investigators will follow participants longitudinally for 6 months. Participants will be instructed and incentivized to present to one of the study clinics when a fever develops, where they will be evaluated, tested, and treated, if positive, for malaria. Participants will also be followed monthly for routine surveillance.

Being tested
Factory-treated lesu, Soaked lesu, Untreated lesu
Keywords
Lesu, Malaria, Permethrin
Medical subject headings
Malaria, Falciparum, Malaria

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Factory-treated lesuOther

    Patterned cotton-blend fabric will be obtained and treated with 0.52% permethrin at Perimeter Insect Guard. After treatment, the material will be cut into 2 x 1 meter swathes

  • Soaked lesuOther

    Wraps will be soaked in 1.0% permethrin solution donated by Sawyer Products (Safety Harbor, FL) in accordance with the manufacturer's instructions and allowed to dry. The material will be cut into 2 x 1 meter swathes

  • Untreated lesuOther

    Untreated fabric of identical appearance (i.e., color and pattern) will be similarly cut and packaged for use

Study groups in NCT07903324
Study groupRoleWhat they receive
Receives factory-treated permethrin lesuExperimentalReceives factory-treated (0.52%) permethrin-treated wrap for 6 months
Receives: Other: Factory-treated lesu
Receives soaked permethrin lesuExperimentalReceives soaked (1%) permethrin-treated wrap for 6 months
Receives: Other: Soaked lesu
Receives untreated lesuSham comparatorReceives the untreated lesu for 6 months
Receives: Other: Untreated lesu

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of clinical malaria in children

    Acute febrile illness defined as fever (temperature ≥38.0 Celsius) or fever reported in past 24 hours AND positive malaria rapid diagnostic test (RDT), confirmed by light microscopy (performed later), at scheduled or unscheduled study clinic visit

    Measured: From enrollment to Month 6

Secondary outcomes (34)
  1. Incidence of hospitalizations due to malaria

    Incidence of admissions from clinic after a positive malaria RDT

    Measured: From enrollment to Month 6

  2. Incidence of hospitalizations due to any cause

    Incidence of admissions from clinic after a positive malaria RDT

    Measured: From enrollment to Month 6

  3. Number of deaths due to any cause

    Incidence of admissions from clinic after a positive malaria RDT

    Measured: From enrollment to Month 6

  4. Number of deaths due to malaria

    Incidence of admissions from clinic after a positive malaria RDT

    Measured: From enrollment to Month 6

  5. Incidence of non-malarial febrile episodes in children

    Incidence of participants experiencing acute febrile illness and negative malaria RDT at a scheduled or unscheduled study visit.

    Measured: From enrollment to Month 6

  6. Wrap attrition

    The number of wraps lost or damaged and requiring replacement.

    Measured: From enrollment to Month 6

  7. Off-target use of wraps

    Self-reported use for other purposes or use with other household members

    Measured: From enrollment to Month 6

  8. Incidence of malaria among mothers or other children (age < 5) in the household

    Acute febrile illness defined as fever (temperature ≥38.0 Celsius) or fever reported in past 24 hours AND positive malaria rapid diagnostic test (RDT) at scheduled or unscheduled study clinic visit

    Measured: From enrollment to Month 6

  9. Perception of intervention

    The median scores of the first 4 Likert-scale questions on the interview (e.g. Overall Experience). Higher scores indicate a more positive perception.

    Measured: Month 6

  10. Number of adverse reactions to wraps

    Counts of the top 5 most common adverse reactions reported by participants on questionnaires and assessed by clinic staff.

    Measured: From enrollment to Month 6

  11. Number of participants with care-seeking events attributable to the wrap

    Number of participants with care-seeking events attributable to the wrap.

    Measured: From enrollment to Month 6

  12. Number of participants with hospitalizations attributable to the wrap

    Number of participants with hospitalizations attributable to the wrap

    Measured: From enrollment to Month 6

  13. Number of participants with death attributable to the wrap

    Number of participants with death attributable to the wrap

    Measured: From enrollment to Month 6

  14. Change in child's height-for-weight

    Change in Z-score for height-for-weight. A height-for-weight Z-score indicates how a child's height compares with a reference population of children of the same weight. A score of 0 represents the reference average; positive values indicate above-average height-for-weight, and negative values indicate below-average height-for-weight. Z = 0: Average height-for-weight in the reference population Z = +1: One standard deviation above the reference average Z = -1: One standard deviation below the reference average Z = -2: Substantially below the reference average

    Measured: Enrollment, Month 3, Month 6

  15. Change in child's height-for-age

    Change in Z-score for height-for-age. A height-for-age Z-score indicates how a child's height compares with a reference population of children of the same age. A score of 0 represents the reference average; positive values indicate above-average height-for-age, and negative values indicate below-average height-for-age. Z = 0: Average height-for-age in the reference population Z = +1: One standard deviation above the reference average Z = -1: One standard deviation below the reference average Z = -2: Substantially below the reference average

    Measured: Enrollment, Month 3, Month 6

  16. Change in child's weight-for-age

    Change in Z-score for weight-for-age. Change in Z-score for weight-for-age. A weight-for-age Z-score indicates how a child's weight compares with a reference population of children of the same age. A score of 0 represents the reference average; positive values indicate above-average weight-for-age, and negative values indicate below-average weight-for-age. Z = 0: Average weight-for-age in the reference population Z = +1: One standard deviation above the reference average Z = -1: One standard deviation below the reference average Z = -2: Substantially below the reference average

    Measured: Enrollment, Month 3, Month 6

  17. Change in child's acute malnutrition

    Change in Mid-upper arm circumference (MUAC).

    Measured: From enrollment to Month 6

  18. Change in child's median score on the Mullen Scales of Early Learning

    Change in median composite scores on the Mullen Scales of Early Learning. The Early Learning Composite from the Mullen Scales of Early Learning (MSEL) will be used to measure developmental functioning. The Early Learning Composite (ELC) is a standardized composite score derived from the 5 subtests measured on the MSEL. It has a mean of 100 and a standard deviation of 15. Higher scores indicate stronger performance.

    Measured: From enrollment to Month 6

  19. Change in child's mean score on the Mullen Scales of Early Learning

    Change in mean composite scores on the Mullen Scales of Early Learning. The Early Learning Composite from the Mullen Scales of Early Learning (MSEL) will be used to measure developmental functioning. The Early Learning Composite (ELC) is a standardized composite score derived from the 5 subtests measured on the MSEL. It has a mean of 100 and a standard deviation of 15. Higher scores indicate stronger performance.

    Measured: From enrollment to Month 6

  20. Change in child's percentile on the Developmental Profile 4: Physical Scale

    Performance on the Physical subscale of the Developmental Profile 4, which includes items measuring gross- and fine-motor skills, coordination, strength, stamina, and flexibility. Expressed as a percentile from 0 to 100%, where a score of 50% indicates that the child performs equal to their same age peers, a score above 50% indicates they perform better than their same age peers, and a score below 50% indicates they perform worse than their same age peers.

    Measured: From enrollment to Month 6

  21. Change in child's percentile on the Developmental Profile 4: Adaptive Behavior Scale

    Performance on the Adaptive Behavior subscale of the Developmental Profile 4, which includes items measuring age-appropriate independent functioning. Expressed as a percentile from 0 to 100%, where a score of 50% indicates that the child performs equal to their same age peers, a score above 50% indicates they perform better than their same age peers, and a score below 50% indicates they perform worse than their same age peers.

    Measured: From enrollment to Month 6

  22. Change in child's percentile on the Developmental Profile 4: Social-Emotional Scale

    Performance on the Social-Emotional subscale of the Developmental Profile 4, which includes items measuring skills related to interpersonal behavior and demonstration of social and emotional competence. Expressed as a percentile from 0 to 100%, where a score of 50% indicates that the child performs equal to their same age peers, a score above 50% indicates they perform better than their same age peers, and a score below 50% indicates they perform worse than their same age peers.

    Measured: From enrollment to Month 6

  23. Change in child's percentile on the Developmental Profile 4: Cognitive Scale

    Performance on the Cognitive subscale of the Developmental Profile 4, which includes items measuring perception, concept development, number relations, reasoning, memory, classification, time concepts, and related mental acuity tasks. Expressed as a percentile from 0 to 100%, where a score of 50% indicates that the child performs equal to their same age peers, a score above 50% indicates they perform better than their same age peers, and a score below 50% indicates they perform worse than their same age peers

    Measured: From enrollment to Month 6

  24. Change in child's percentile on the Developmental Profile 4: Communication Scale

    Performance on the Communication subscale of the Developmental Profile 4, which reflects the ability to understand spoken and written language as well as to use both verbal and nonverbal skills to communicate. Expressed as a percentile from 0 to 100%, where a score of 50% indicates that the child performs equal to their same age peers, a score above 50% indicates they perform better than their same age peers, and a score below 50% indicates they perform worse than their same age peers.

    Measured: From enrollment to Month 6

  25. Change in child's growth score on the Developmental Profile 4: Physical Scale

    Performance on the Physical subscale of the Developmental Profile 4, which is expressed as a a raw score from 40 to 160 that is designed specifically to track progress and monitor developmental change over time, where higher scores indicate better performance

    Measured: From enrollment to Month 6

  26. Change in child's growth score on the Developmental Profile 4: Adaptive Behavior Scale

    Performance on the Adaptive Behavior subscale of the Developmental Profile 4, which is expressed as a a raw score from 40 to 160 that is designed specifically to track progress and monitor developmental change over time, where higher scores indicate better performance

    Measured: From enrollment to Month 6

  27. Change in child's growth score on the Developmental Profile 4: Social-Emotional Scale

    Performance on the Social-Emotional subscale of the Developmental Profile 4, which is expressed as a a raw score from 40 to 160 that is designed specifically to track progress and monitor developmental change over time, where higher scores indicate better performance

    Measured: From enrollment to Month 6

  28. Change in child's growth score on the Developmental Profile 4: Cognitive Scale

    Performance on the Cognitive subscale of the Developmental Profile 4, which is expressed as a a raw score from 40 to 160 that is designed specifically to track progress and monitor developmental change over time, where higher scores indicate better performance

    Measured: From enrollment to Month 6

  29. Change in child's growth score on the Developmental Profile 4: Communication Scale

    Performance on the Communication subscale of the Developmental Profile 4, which is expressed as a a raw score from 40 to 160 that is designed specifically to track progress and monitor developmental change over time, where higher scores indicate better performance

    Measured: From enrollment to Month 6

  30. Change in child's age equivalent on the Developmental Profile 4: Physical Scale

    Performance on the Physical subscale of the Developmental Profile 4, which translates the child's performance to the age at which an average child achieves those same raw scores. Expressed as a metric in the format X:Y where X equals the number of years old, and Y equals a number between 0 and 11. Values higher than the child's age-equivalence reflects developmental functioning consistent with that of older children

    Measured: From enrollment to Month 6

  31. Change in child's age equivalent on the Developmental Profile 4: Adaptive Behavior Scale

    Performance on the Adaptive Behavior subscale of the Developmental Profile 4, which translates the child's performance to the age at which an average child achieves those same raw scores. Expressed as a metric in the format X:Y where X equals the number of years old, and Y equals a number between 0 and 11. Values higher than the child's age-equivalence reflects developmental functioning consistent with that of older children

    Measured: From enrollment to Month 6

  32. Change in child's age equivalent on the Developmental Profile 4: Social-Emotional Scale

    Performance on the Social-Emotional subscale of the Developmental Profile 4, which translates the child's performance to the age at which an average child achieves those same raw scores. Expressed as a metric in the format X:Y where X equals the number of years old, and Y equals a number between 0 and 11. Values higher than the child's age-equivalence reflects developmental functioning consistent with that of older children.

    Measured: From enrollment to Month 6

  33. Change in child's age equivalent on the Developmental Profile 4: Cognitive Scale

    Performance on the Cognitive subscale of the Developmental Profile 4, which translates the child's performance to the age at which an average child achieves those same raw scores. Expressed as a metric in the format X:Y where X equals the number of years old, and Y equals a number between 0 and 11. Values higher than the child's age-equivalence reflects developmental functioning consistent with that of older children

    Measured: From enrollment to Month 6

  34. Change in child's age equivalent on the Developmental Profile 4: Communication Scale

    Performance on the Communication subscale of the Developmental Profile 4, which translates the child's performance to the age at which an average child achieves those same raw scores. Expressed as a metric in the format X:Y where X equals the number of years old, and Y equals a number between 0 and 11. Values higher than the child's age-equivalence reflects developmental functioning consistent with that of older children.

    Measured: From enrollment to Month 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2026
  2. Study start1 Sep 2027 (estimated)
  3. Primary completion1 Sep 2029 (estimated)
  4. Study completion1 Sep 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
1,350 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07903324
Sponsor's protocol ID
26-2587
Status last verified
Oct 2026
First submitted
21 Oct 2026
Last updated
29 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Deidentified individual data that supports the results may be shared beginning 9 and continuing for 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.

Questions about this trial

What is this clinical trial studying?

A study testing Factory-treated lesu, Soaked lesu and Untreated lesu in people with Malaria (Plasmodium Falciparum) and Malaria Incidence, run by University of North Carolina, Chapel Hill at 1 site in Uganda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ross Boyce, MD, MSc (919-966-2537, ross_boyce@med.unc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of clinical malaria in children (time frame: From enrollment to Month 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in